Celsion discloses the positive data of thermodox in the phase II clinical stage of breast cancer
-
Last Update: 2014-02-28
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: China Council for the promotion of drugs 2014-02-28 February 27, 2014, celsion company announced that thermodox treatment of recurrent chest wall breast cancer is in the process of open label phase II test, with the positive data of the design The trial will recruit 20 patients from five clinical centers in the United States and assess the efficacy of thermodox in combination with hyperthermia According to the existing data, the local control rate was 80% in 5 patients, especially in 2 patients with complete remission, 2 patients with partial remission and 1 patient with stable condition This data is consistent with the data of rcwbc in phase I and phase I test published previously Thermodox is a doxorubicin thermosensitive liposome At present, Zhejiang Haihe and celsion are jointly developing the drug Original link: http://www.rttnews.com/2277867/cell-reeveals-positive-interim-data-from-ph-2-density-trial-in-breast-cancer.aspx
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
